HIV Infections Clinical Trial
Official title:
A Pilot Study of the Combination of Retinoic Acid and Interferon-Alpha2a for the Treatment of Lymphoproliferative Disorders in Children With Immunodeficiency Syndromes
Patients with congenital or acquired immunodeficiencies are at an increased risk to develop
polyclonal or oligoclonal lymphoid malignancies. Some develop a lymphoproliferative disorder
that can follow a clinically aggressive course and may represent a pre-malignant lesion.
Although most of these lymphoproliferative disorders are of B-cell origin, T-cell or
non-B-non-T-cell processes have also been observed. The pathogenesis is only partially
understood.
In the case of pre-malignant conditions it is often difficult to know when and whether a
therapeutic intervention is necessary and a careful consideration of potential
treatment-associated morbidity is indicated. Therapies have ranged from influencing the
possible infectious etiology (by treating with acyclovir), decreasing the amount of
immunosuppression (in transplant patients), to the use of immunomodulatory agents, including
interferons and interleukins. Recent data have indicated that the use of differentiating
agents, such as the retinoids, might offer yet another treatment option. In the current
study we will try to get a better understanding of the pathogenesis and natural course of
lymphoproliferative disorders in immunodeficient children.
The study will have two parts: an initial observation period to obtain information on the
natural course of these disorders, and then a six month treatment period with the
combination of a differentiating agent (13-cis-retinoic acid was used until
all-trans-retinoic acid became available on 7/96) with an immunomodulatory agent
(interferon-alpha2a, IFN-alpha2a).
Status | Completed |
Enrollment | 30 |
Est. completion date | December 2000 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
DISEASE CHARACTERISTICS: Congenital or acquired immunodeficiency (including HIV-1 infection) with a lymphoproliferative disorder (LPD) of any of the following types: Severe and/or progressive lymphadenopathy with hypergammaglobulinemia. Diffuse infiltrative lymphocytosis syndrome. Clinically symptomatic pulmonary lymphoid hyperplasia/lymphocytic interstitial pneumonitis. Polyclonal B-cell LPD. No patients with malignant lymphoma. No active opportunistic infection requiring acute intervention at entry. THERAPY: Biologic Therapy: At least 30 days since immunomodulating agents or biological response modifiers, e.g.: Interleukin-2, Interferons, Growth hormone, Insulin-like growth factor 1. Requirement waived for intravenous immunoglobulins for hypogammaglobulinemia. Concurrent post-transplant immunosuppressants allowed. Doses stable for at least 4 weeks prior to entry. Chemotherapy: At least 30 days since chemotherapy. Endocrine Therapy: Concurrent corticosteroids allowed only for lymphocytic interstitial pneumonitis or an autoimmune process. Doses stable for more than 4 weeks prior to entry. Radiotherapy: At least 30 days since radiotherapy. Surgery: Not specified. Antiretroviral therapy (in patients with HIV infection): Approved anti-HIV medication required. Initiated at least 8 weeks prior to entry. Continued throughout protocol treatment. Prophylaxis for Pneumocystis carinii pneumonia and/or Mycobacterium avium-intracellulare allowed. Maintenance antifungal or antiviral therapy allowed. PATIENT CHARACTERISTICS: Age: Under 18. Performance status: Not specified. One or more of the following laboratory findings (within 4 weeks of starting retinoic acid and interferon-alpha , and which have not resolved within 2 weeks of starting): Creatinine greater than 2 times the upper limit of normal; Liver transaminases greater than 5 times the upper limit of normal (children with chronically elevated liver enzymes with a proven etiology can be enrolled, but will not be evaluable for liver toxicity); or Bilirubin greater than 3 times the upper limit of normal. Patients receiving treatment for an acute infection must have completed therapy at least 14 days prior to starting therapy with retinoic acid and interferon-alpha. OTHER: Able to swallow capsules. No requirement for drugs suspected of causing pseudotumor cerebri for which alternatives cannot be substituted, e.g.: Tetracycline, Nalidixic acid, Nitrofurantoin, Phenytoin, Lithium, Amiodarone, Vitamin A (except as a multivitamin supplement component). No critical or clinically unstable illness. No pregnant or nursing women. Effective contraception encouraged in fertile patients. Parent or legal guardian available to give informed consent and deemed sufficiently reliable to return for followup visits. No critically ill or critically unstable children. |
Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | National Cancer Institute (NCI) | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Avilés A, Díaz-Maqueo JC, García EL, Talavera A, Guzmán R. Maintenance therapy with interferon alfa 2b in patients with diffuse large cell lymphoma. Invest New Drugs. 1992 Nov;10(4):351-5. — View Citation
Sidell N, Taga T, Hirano T, Kishimoto T, Saxon A. Retinoic acid-induced growth inhibition of a human myeloma cell line via down-regulation of IL-6 receptors. J Immunol. 1991 Jun 1;146(11):3809-14. — View Citation
Su IJ, Cheng AL, Tsai TF, Lay JD. Retinoic acid-induced apoptosis and regression of a refractory Epstein-Barr virus-containing T cell lymphoma expressing multidrug-resistance phenotypes. Br J Haematol. 1993 Dec;85(4):826-8. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |